Loading...
NPI 1124128046 · Dothan, AL · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
John Dunn is a hematology & oncology physician provider located in Dothan, Alabama. This profile covers 49 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | John Dunn |
| Address | 287 Healthwest Dr |
| City | Dothan |
| State | AL |
| ZIP | 36303 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | September 22, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.9M |
| Medicaid | $0 |
JOHN DUNN is a Hematology & Oncology Physician based in DOTHAN, AL with an NPI enumerated on 2006-09-22 (~20 years ago). His reported lifetime Medicare revenue is $1.9M while Medicaid revenue is $0, making his billings effectively single-payer (Medicare) in scale and indicating little to no Medicaid-facing activity on file.
Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 63.4% of this provider's total Medicare revenue. Those top three are J0897 ($469.8K, 25.9%), J9271 ($447.2K, 24.6%), and J1569 ($234.1K, 12.9%), showing a small set of therapy codes driving the majority of Medicare dollars.
The code mix indicates an outpatient infusion/oncology operation: high-revenue oncology and bone-targeted agents like J9271 (pembrolizumab) and J0897 (denosumab) appear alongside chemotherapy administration codes (96413, 96401) and infusion management codes (96365, 96367). Supportive-care and biologic therapy billing (J1569 immune globulin, J0881 darbepoetin alfa and antiemetics such as J0185) further suggest the practice administers systemic cancer treatments and related supportive infusions on-site.
Competitive standing varies by product: J0897 is an extreme outlier nationally, ranking #139 of 10057 providers (99th percentile) and showing unusually high national volume for denosumab. By contrast, J9271 ranks #1128 of 1841 providers (38th percentile) and is described as typical/unremarkable for pembrolizumab volume, while J1569 ranks #113 of 542 providers (79th percentile) indicating above-typical participation but not an extreme outlier.
Several administration and evaluation codes are notably above typical national volumes, supporting the high-throughput infusion interpretation: 99214 ranks #13988 of 479517 providers (97th percentile; notably above typical), 96413 ranks #424 of 7514 providers (94th percentile; notably above typical), and 96367 ranks #97 of 4032 providers (98th percentile; notably above typical). These ranks imply frequent on-site E/M and infusion activity relative to peers.
The provider bills very large claim volumes for some low-unit-price medications, for example J0881 shows 24.6K claims for $49.2K revenue and J0185 shows 22.1K claims for $22.1K revenue, indicating routine, high-frequency administration of supportive or low-dollar drugs. This pattern—high claim counts with low per-claim payments—aligns with regular outpatient infusion workflows and recurring supportive-care dosing.
From a payer/contracting perspective, the $1.9M concentrated in Medicare with $0 in Medicaid means payer mix and reimbursement negotiations should prioritize Medicare arrangements and value-based or fee arrangements tied to Medicare performance; there is no Medicaid billing footprint to leverage in-state. The provider’s long-tenure NPI (2006-09-22, ~20 years) suggests an established practice likely to be operationally stable.
Taken together, the extreme national rank on J0897 plus substantial shares for J9271 and J1569 position this clinician as a high-volume regional infusion oncology provider with a particular concentration in denosumab administration. For network strategy or competitive analysis, the combination of an outsized denosumab volume, meaningful pembrolizumab and immune-globulin billing, and high E/M and infusion ranks signals a center focused on systemic oncology care and supportive biologic therapies.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
49 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | 26,100 | $20 | $469.8K |
| J9271 | Injection, pembrolizumab, 1 mg | 10,400 | $40 | $447.2K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 6,690 | $40 | $234.1K |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 4,620 | $30 | $115.5K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 4,260 | $20 | $89.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 920 | $90 | $81.1K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 4,100 | $20 | $69.7K |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 14,400 | $1 | $57.6K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 590 | $90 | $52.3K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 24,600 | $1 | $49.2K |
Showing 1–10 of 49
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 49 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
49 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 27 | 30 | 19,900 | $40 | $827.2K |
| J1569 | 4 | 10 | 5,120 | $40 | $179.3K |
| J1449 | 1 | 10 | 4,550 | $30 | $115.7K |
| J0897 | 4 | 200 | 3,120 | $20 | $97.7K |
| J1627 | 2 | 10 | 14,400 | $1 | $69.9K |
| J1437 | 12 | 40 | 3,000 | $20 | $59.1K |
| Q5119 | 1 | 10 | 2,280 | $20 | $55.9K |
| J0881 | 3 | 30 | 7,720 | $1 | $24.1K |
| 96413 | 10 | 150 | 150 | $90 | $20.2K |
| 99214 | 216 | 7,330 | 120 | $80 | $16.8K |
Showing 1–10 of 49
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 50 | $0 | $0 |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 110 | $0 | $0 |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 30 | $0 | $0 |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 20 | $0 | $0 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 30 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,824 | 1,990 | 560 | $40 | $185.6K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 305 | 370 | 1,540 | $10 | $65K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 12 | 20 | 290 | $20 | $9.1K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 414 | 520 | 300 | $1 | $2.7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 13 | 20 | 80 | $1 | $170 |
Other providers in the same ZIP code as John Dunn, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.